Pharmaceuticals Policy and Law
ISSN: 1389-2827 Volume 12; 4 issues
Institutional subscription (print and online) for 2010: €358 / US$505 (including postage and handling)
Click on the subscribe button for more options, including personal subscription prices.
Status Report: Last issue (volume 11:4) online on 03 September 2009
Next issue (volume 12:1) scheduled for December 2009
Aims and Scope
Editorial Board
Submission of Manuscripts
Abstracted in
Download flyer for this journal
Editor-in-Chief
Prof. José Luis Valverde
Chair Jean Monnet, EU: 'Europe of the Health'
University of Granada
Faculty of Pharmacy
Campus de la Cartuja sn
Granada 18071
Spain
Tel.: +34 958 24 38 98
Fax:+34 958 24 89 08
E-mail: jlvalver@ugr.es
Advisory Board
| Dr. Rodica Badescu, Romania | Prof. Francis B. Palumbo, USA |
| Dr. J. Lyle Bootman, USA | Mr. Enrique Sánchez de León Pérez, Spain |
| Mr. Philippe Brunet, Belgium | Mr. Fernand Sauer, France |
| Mr. Patrick Deboyser, Belgium | Prof. Walter Schwerdtfeger, Germany |
| Ms. P. Ann Hoppe, USA | Dr. Milan Smid, Czech Republic |
| Ms. Linda Horton, USA | Prof. José María Suñé Arbussá, Spain |
| Prof. Tatsuo Kurokawa, Japan | Mr. Josep Torrent-Farnell, United Kingdom |
| Mr. Alan G. Minsk, USA | Mr. Hannes Wahlroos, Finland |
See instructions to authors. The new international review, Pharmaceuticals policy and law, appears with the aim of studying and evaluating the legal status of medicinal products in the European Union, and its implications in other markets such as the USA and Japan, without neglecting the specific problems of developing countries. Pharmaceuticals policy and law intends to participate in the process of world convergence of pharmaceutical legislation helped by a network of academic centers specializing in pharmaceutical law, without omitting a scientific, economic and social approach to medicinal products.
The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.
Abstracted in
EBSCO database,
Inspec
Backvolumes
1-11